Hepatitis c therapies

Abstract

The invention provides methods for treating hepatitis C viral infections and related viral infections, as well as compounds and compositions that are useful for treating such infections.

What is claimed: 
     
         1 . A compound of the formula: 
       
         
           
           
               
               
           
         
       
       wherein:
 R is OR a , SR a , NR e R f , NR a NR b R c , alkyl, alkenyl, alkynyl, aryl, (CH 2 ) n NR a R b , (CH 2 ) n OR a , C(═NR a )NR b R c , (CH 2 ) n —CH(NHR a )CO 2 R b , (CH 2 ) n —S-alkyl, (CH 2 ) n —S-aryl, Cl, F, Br, I, CN, COOR a , CONR a R b , NHC(═NR a )NHR b , NR a OR b , NR a NO, NHCONHR a , NR a N═NR b , NR a N═CHR b , NR a C(O)NR b R c , NR a C(S)NR b R c , NR a C(O)OR b , CH═N—OR a , NR a C(═NH)NR b R c , NR a C(O)NR b NR C R d , O—C(O)R a , OC(O)—OR a , ONH—C(O)O-alkyl, ONHC(O)O-aryl, ONR a R b , SNR a R b , S—ONR a R b , or SO 2 NR a R b ; 
 n is 0, 1, 2, 3, 4, or 5; 
 R 1  is H, NR a R b , Cl, F, OR a , SR a , NHCOR a , NHSO 2 R a , NHCONHR a , CN, alkyl, aryl, ONR a R b , or NR a C(O)OR b ; 
 R 2  is H and R 3  is OH; or R 2  is OH and R 3  is H; 
 R 4  is OH, alkyl-O—, alkylC(═O)O, alkyl-S—, or alkylC(═O)—S—; 
 R 5  is OH, alkyl-O—, alkylC(═O)O, alkyl-S—, or alkylC(═O)—S— 
 R a , R b , R c , and R d  are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, acyl, SO 2 -alkyl and NO; or R a  and R b  together with the nitrogen to which they are attached form a pyrrolidino, piperidino, piperazino, azetidino, morpholino, pyrrolino, or thiomorpholino ring; or R b  and R c  together with the nitrogen to which they are attached form a pyrrolidino, piperidino, piperazino, azetidino, morpholino, pyrrolino, or thiomorpholino ring; 
 R e  is alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, acyl, SO 2 -alkyl or NO; and R f  is H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, acyl, SO 2 -alkyl and NO; or R e  and R f  together with the nitrogen to which they are attached form a pyrrolidino, piperidino, piperazino, azetidino, morpholino, pyrrolino, or thiomorpholino ring; which ring is optionally substituted with one or more halo, hydroxyl, alkyl, alkenyl, or alkynyl; 
 wherein any alkyl, cycloalkyl, alkenyl, alkynyl, or acyl is optionally substituted with 1 to 3 substituents selected from the group consisting of alkoxy, acyl, acylamino, acyloxy, oxyacyl, amino, substituted amino, aminoacyl, aryl, aryloxy, cyano, halogen, hydroxyl, nitro, N 3 , carboxyl, carboxyl esters, thiol, thioalkyl, thioaryl, thioheteroaryl, thiocycloalkyl, thioheterocyclic, cycloalkyl, heteroaryl, and heterocyclic; 
 and wherein any aryl, heteroaryl, or heterocycle is optionally substituted with 1 to 3 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, acyl, acylamino, acyloxy, oxyacyl, amino, substituted amino, aminoacyl, aryl, aryloxy, cyano, halogen, hydroxyl, nitro, N 3 , carboxyl, carboxyl esters, thiol, thioalkyl, thioaryl, thioheteroaryl, thiocycloalkyl, thioheterocyclic, cycloalkyl, heteroaryl, and heterocyclic; 
 or a pharmaceutically acceptable salt or prodrug thereof. 
 
     
     
         2 . The compound of  claim 1  wherein R is OR a , Cl, SR a , NR e R f , aryl or NR a NR b R c . 
     
     
         3 . The compound of  claim 1  wherein R is hydroxy, chloro, methoxy, mercapto, methylthio, methylamino, isopropylamino, propylamino, ethylamino, dimethylamino, cyclopropylamino, 2-aminoethylamino, 1-(2-hydroxyethyl)hydrazino, hydrazino, 1-methylhydrazino, azetidino, pyrrolidino, imidazolylpropylamino, pyrrolino, morpholino, piperazino, hydroxyethylamino, bis-hydroxyethylamino, hydroxypropylamino, hydroxyethylpyrrolidino, or 1-methyl-2-hydroxyethylamino. 
     
     
         4 . The compound of  claim 1  wherein R is NR e R f . 
     
     
         5 . The compound of  claim 1  which is 4-methylamino-7-β-(D-ribofuranosyl)-furo[3,2-d]pyrimidine; 4-Ethylamino-7-β-(D-ribofuranosyl)-furo[3,2-d]pyrimidine; 4-Isopropylamino-7-β-(D-ribofuranosyl)-furo[3,2-d]pyrimidine; 4-Dimethylamino-7-β-(D-ribofuranosyl)-furo[3,2-d]pyrimidine; 4-n-Propylamino-7-β-(D-ribofuranosyl)-furo[3,2-d]pyrimidine; 4-(N-3-pyrrolino)-7-β-(D-ribofuranosyl)-furo[3,2-d]pyrimidine; 4-(2-hydroxymethylpyrrolidino)-7-β-(D-ribofuranosyl)-furo[3,2-d]pyrimidine; 4-(3-N-imidazolyl-n-propylamino)-7-β-(D-ribofuranosyl)-furo[3,2-d]pyrimidine; 4-N-morpholino-7-β-(D-ribofuranosyl)-furo[3,2-d]pyrimidine; 4-N-piperazino-7-β-(D-ribofuranosyl)-furo[3,2-d]pyrimidine; 4-(hydroxyethylamino)-7-β-(D-ribofuranosyl)-furo[3,2-d]pyrimidine; 4-(N-bis-hydroxyethylamino)-7-β-(D-ribofuranosyl)-furo[3,2-d]pyrimidine; 4-(3-hydroxypropylamino)-7-β-(D-ribofuranosyl)-furo[3,2-d]pyrimidine; or 4-(2-hydroxy-1-methyl-ethylamino)-7-β-(D-ribofuranosyl)-furo[3,2-d]pyrimidine; 
       or a pharmaceutically acceptable salt or prodrug thereof. 
     
     
         6 . The compound of  claim 1  which is a prodrug. 
     
     
         7 . The compound of  claim 1  that comprises one or more mono-, di-, or tri-phosphate groups. 
     
     
         8 . The compound of  claim 1  that comprises one or more mono-phosphate groups. 
     
     
         9 . The compound of  claim 7  wherein the compound is a prodrug. 
     
     
         10 . The compound of  claim 7  wherein one or more phosphorous atoms of the one or more pendent mono-, di-, or tri-phosphate groups is bonded to one or more alkoxy or aryloxy groups. 
     
     
         11 . The compound of  claim 7  wherein one or more phosphorous atoms of the pendent mono-, di-, or tri-phosphate groups is bonded to one or more groups R y —O—; wherein each R y  is independently a 1-20 carbon branched or unbranched, saturated or unsaturated chain, wherein one or more of the carbon atoms is optionally replaced with —O— or —S— and wherein one or more of the carbon atoms is optionally substituted with oxo (═O) or thioxo (═S). 
     
     
         12 . The compound of  claim 7  wherein one or more phosphorous atoms of the one or more pendent mono-, di-, or tri-phosphate groups is bonded to one or more groups R z —N—; wherein each R z  is a residue of an amino acid. 
     
     
         13 . The compound of  claim 12  wherein the amino acid is a natural amino acid. 
     
     
         14 . The compound of  claim 7  which comprises one or more groups of formula: 
       
         
           
           
               
               
           
         
       
       wherein:
 R 15  is H, alkyl, aryl, cycloalkyl, heteroaryl, heterocyclic, or an amino acid; 
 R 16  is H, aryl, or heteroaryl; and R 17  is H, halogen, CN, —CO—R 20 , —CON(R 21 ) 2 , —CO 2 R 20 , —SO 2 R 20 , —SO 2 N(R 21 ) 2 , —OR 21 , —SR 21 , —R 21 , —N(R 21 ) 2 , —O—COR 20 , —O—CO 2 R 20 , —SCOR 20 , —S—CO 2 R 20 , —NHCOR 21 , —NHCO 2 R 21 , —(CH 2 ) p —OR 22 , or —(CH 2 ) p —SR 22 ; or R 16  and R 17  are connected via an additional 3-5 atoms to form a cyclic group, optionally containing one heteroatom, that is fused to an aryl group at the beta and gamma position to the O attached to the phosphorus; or R 17  and R 18  are connected as described below; 
 R 18  and R 19  are each independently H, alkyl, aryl, aralkyl, aryl, or heteroaryl; or R 18  and R 19  are connected via an additional 2-5 atoms to form a cyclic group, optionally containing 0-2 heteroatoms; or R 17  and R 18  are connected via an additional 3-5 atoms to form a cyclic group, optionally containing one heteroatom and R 19  is H, alkyl, aryl, aralkyl, aryl or heteroaryl; 
 R 20  is alkyl, aryl, or arylalkyl; 
 R 21  is H, alkyl, aryl, or arylalkyl; 
 R 22  is H or lower acyl; 
 p is an integer from 2-3; 
 wherein any alkyl, cycloalkyl, alkenyl, alkynyl, or acyl is optionally substituted with 1 to 3 substituents selected from the group consisting of alkoxy, acyl, acylamino, acyloxy, oxyacyl, amino, substituted amino, aminoacyl, aryl, aryloxy, cyano, halogen, hydroxyl, nitro, N 3 , carboxyl, carboxyl esters, thiol, thioalkyl, thioaryl, thioheteroaryl, thiocycloalkyl, thioheterocyclic, cycloalkyl, heteroaryl, and heterocyclic; 
 and wherein any aryl, heteroaryl, or heterocycle is optionally substituted with 1 to 3 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, acyl, acylamino, acyloxy, oxyacyl, amino, substituted amino, aminoacyl, aryl, aryloxy, cyano, halogen, hydroxyl, nitro, N 3 , carboxyl, carboxyl esters, thiol, thioalkyl, thioaryl, thioheteroaryl, thiocycloalkyl, thioheterocyclic, cycloalkyl, heteroaryl, and heterocyclic. 
 
     
     
         15 . The compound of  claim 1  which is a prodrug wherein one or more of R 2 , R 3 , and R 4  is acyloxy, acylamino or R—O; wherein R is a carboxy-linked amino acid. 
     
     
         16 . A pharmaceutical composition comprising a compound as described in  claim 1 , or a pharmaceutically acceptable salt or prodrug thereof; and a pharmaceutically acceptable carrier. 
     
     
         17 . The composition of  claim 16  which further comprises one or more additional anti-viral agents, immune modulators, or interferon inducers. 
     
     
         18 . The composition of  claim 17  wherein the one or more anti-viral agents are selected from ribavirin, levovirin, viramidine, thymosin alpha-1, an inhibitor of a serine proteases, an inhibitor of inosine monophosphatedehydrognease, interferon-α, and pegylated interferon-α (peginterferon-α). 
     
     
         19 . The composition of  claim 16  which further comprises one or more additional HCV polymerase inhibitors. 
     
     
         20 . The composition of  claim 16  which further comprises one or more protease inhibitors. 
     
     
         21 . The composition of  claim 16  which further comprises ribavirin. 
     
     
         22 . The composition of  claim 16  which further comprises interferon-α or pegylated interferon-α (peginterferon-α). 
     
     
         23 . A method for treating a viral infection selected from hepatitis B, hepatitis C, Polio, Coxsackie A and B, Rhino, Echo, small pox, Ebola, and West Nile in an animal, comprising administering to the animal an effective amount of a compound of formula I: 
       
         
           
           
               
               
           
         
       
       wherein:
 X═N or CH; 
 Y═O, S or N—R 4 ; 
 R is OR 3 , SR 3 , NR 3 R 4 , NR 3 NR 4 R 5 , alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, (CH 2 ) n NR a R b , (CH 2 ) n OR a , C(═NR a )NR b R c , (CH 2 ) n —CH(NHR 3 )CO 2 R 4 , (CH 2 ) n —S-alkyl, (CH 2 ) n —S-aryl, Cl, F, Br, I, CN, COOR 3 , CONR 3 R 4 , NHC(═NR 3 )NHR 4 , NR 3 OR 4 , NR 3 NO, NHCONHR 3 , NR 3 N═NR 4 , NR 3 N═CHR 4 , NR 3 C(O)NR 4 R 5 , NR 3 C(S)NR 4 R 5 , NR 3 C(O)OR 4 , CH═N—OR 3 , NR 3 C(═NH)NR 4 R 5 , NR 3 C(O)NR 4 NR 5 R 6 , O—C(O)R 3 , OC(O)—OR 3 , ONH—C(O)O-alkyl, ONHC(O)O-aryl, ONR 3 R 4 , SNR 3 R 4 , S—ONR 3 R 4 , or SO 2 NR 3 R 4 ; 
 n is 0, 1, 2, 3,4, or 5; 
 R 1  is H, NR 3 R 4 , Cl, F, OR 3 , SR 3 , NHCOR 3 , NHSO 2 R 3 , NHCONHR 3 , CN, alkyl, aryl, ONR 3 R 4 , or NR 3 C(O)OR 4 ; 
 R 2  is ribose, 2-deoxyribose; 2-deoxy-2-fluororibose; arabinose; 2-deoxy-2-fluoroarabinose; 2,3-dideoxyribose; 2,3-dideoxy-2-fluoroarabinose; 2,3-dideoxy-3-fluororibose; 2,3-dideoxy-2,3-didehydroribose; 2,3-dideoxy-3-azidoribose; 2,3-dideoxy-3-thiaribose; or 2,3-dideoxy-3-oxaribose; 
 R 3  is H, alkyl, aryl, F, Cl, CN, CO 2 H or NH 2 ; and 
 R 4  is H, OH, alkyl, aryl, —COO-alkyl, CONH 2 , CONH-alkyl, O—C(O)-alkyl, O—C(O)-aryl or alkoxy; 
 R 3 , R 4 , R 5 , and R 6  are independently selected from the group consisting of H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, heterocyclic, aryl, substituted aryl, acyl, substituted acyl, SO 2 -alkyl OH, —COO-alkyl, CONH 2 , CONH-alkyl, O—C(O)-alkyl, O—C(O)-aryl alkoxy and NO; or R 3  and R 4  together with the nitrogen to which they are attached form a pyrrolidino, piperidino, piperazino, azetidino, morpholino, pyrrolino, or thiomorpholino ring; or R 4  and R 5  together with the nitrogen to which they are attached form a pyrrolidino, piperidino, piperazino, azetidino, morpholino, pyrrolino, or thiomorpholino ring; wherein any ring formed by R 3  and R 4  or R 4  and R 5  is optionally substituted with one or more hydroxyl, halo, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, or substituted alkynyl; and 
 R a , R b , and R c  are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, acyl, SO 2 -alkyl and NO; or R a  and R b  together with the nitrogen to which they are attached form a pyrrolidino, piperidino, piperazino, azetidino, morpholino, pyrrolino, or thiomorpholino ring; or R b  and R c  together with the nitrogen to which they are attached form a pyrrolidino, piperidino, piperazino, azetidino, morpholino, pyrrolino, or thiomorpholino ring; 
 or a pharmaceutically acceptable salt or prodrug thereof. 
 
     
     
         24 . The method of  claim 23  wherein the compound of formula I is a compound of the following formula: 
       
         
           
           
               
               
           
         
       
       wherein:
 Y is O or S; 
 R is OR 3 , SR 3 , NR 3 R 4 , NR 3 NR 4 R 5 , alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, (CH 2 ) n —CH(NHR 3 )CO 2 R 4 , Cl, F, Br, I, CN, COOR 3 , CONR 3 R 4 , NHC(═NR 3 )NHR 4 , NR 3 OR 4 , NR 3 NO, NHCONHR 3 , NR 3 N═NR 4 , NR 3 N═CHR 4 , NR 3 C(O)NR 4 R 5 , NR 3 C(S)NR 4 R 5 , NR 3 C(O)OR 4 , CH═N—OR 3 , NR 3 C(═NH)NR 4 R 5 , NR 3 C(O)NR 4 NR 5 R 6 , O—C(O)R 3 , OC(O)—OR 3 , ONH—C(O)O-alkyl, ONHC(O)O-aryl, ONR 3 R 4 , SNR 3 R 4 , S—ONR 3 R 4 , or SO 2 NR 3 R 4 ; 
 n is 0-5; 
 R 1  is H, NR 3 R 4 , Cl, F, OR 3 , SR 3 , NHCOR 3 , NHSO 2 R 3 , NHCONHR 3 , CN, alkyl, aryl, ONR 3 R 4 , or NR 3 C(O)OR 4 ; 
 R 2  is ribose, 2-deoxyribose; 2-deoxy-2-fluororibose; arabinose; 2-deoxy-2-fluoroarabinose; 2,3-dideoxyribose; 2,3-dideoxy-2-fluoroarabinose; 2,3-dideoxy-3-fluororibose; 2,3-dideoxy-2,3-didehydroribose; 2,3-dideoxy-3-azidoribose; 2,3-dideoxy-3-thiaribose; or 2,3-dideoxy-3-oxaribose; and 
 R 3 , R 4 , R 5 , and R 6  are independently selected from the group consisting of H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, heterocyclic, aryl, substituted aryl, acyl, substituted acyl, SO 2 -alkyl and NO; or R 3  and R 4  together with the nitrogen to which they are attached form a pyrrolidino, piperidino, piperazino, azetidino, morpholino, or thiomorpholino ring; or R 4  and R 5  together with the nitrogen to which they are attached form a pyrrolidino, piperidino, piperazino, azetidino, morpholino, or thiomorpholino ring; 
 or a pharmaceutically acceptable salt or prodrug thereof. 
 
     
     
         25 . The method of  claim 23  wherein the compound has the formula: 
       
         
           
           
               
               
           
         
       
       wherein
 X═N or CH; 
 Y═O, S or N—R 4 ; 
 R═OR 5 , NHR 4 , NR 4 R 5 , NHNHR 4 , NR 4 NHR 5 , SR 5 , alkyl, aryl, Cl, NR 4 OR 5 , NR 4 NO, or NHCONHR 4 ; 
 R 1 ═H, NHR 4 , Cl, F, OR 4 , SR 4 , NHCOR 4 , NHSO 2 R 4 , NHCONHR 4 , CN, alkyl, aryl, or NR 4 R 5 ; 
 R 2 =ribose, 2-deoxyribose; 2-deoxy-2-fluororibose; arabinose; 2-deoxy-2-fluoroarabinose; 2,3-dideoxyribose; 2,3-dideoxy-2-fluoroarabinose; 2,3-dideoxy-3-fluororibose; 2,3-dideoxy-2,3-didehydroribose; 2,3-dideoxy-3-azidoribose; 2,3-dideoxy-3-thiaribose; or 2,3-dideoxy-3-oxaribose; 
 R 3 ═H, alkyl, aryl, F, Cl, CN, CO 2 H or NH 2 ; 
 R 4 ═H, OH, alkyl, aryl, —COO-alkyl, CONH 2 , CONH-alkyl, O—C(O)-alkyl, O—C(O)-aryl or alkoxy; 
 R 5 =alkyl, aryl, OH or alkoxy;
 or a pharmaceutically acceptable salt or prodrug thereof. 
 
 
     
     
         26 . The method of  claim 25 , provided that when Y═NH or S and R═NH 2 , OH, SH, alkylamino, alkyloxy, or alkylthio, R 2  is not from ribose or 2-deoxyribose. 
     
     
         27 . The method of  claim 23  wherein the compound has the formula: 
       
         
           
           
               
               
           
         
       
       wherein:
 R is OR a , SR a , NR e R f , NR a NR b R c , alkyl, alkenyl, alkynyl, aryl, (CH 2 ) n NR a R b , (CH 2 ) n OR a , C(═NR a )NR b R c , (CH 2 ) n —CH(NHR a )CO 2 R b , (CH 2 ) n —S-alkyl, (CH 2 ) n —S-aryl, Cl, F, Br, I, CN, COOR a , CONR a R b , NHC(═NR a )NHR b , NR a OR b , NR a NO, NHCONHR a , NR a N═NR b , NR a N═CHR b , NR a C(O)NR b R c , NR a C(S)NR b R c , NR a C(O)OR b , CH═N—OR a , NR a C(═NH)NR b R c , NR a C(O)NR b NR c R d , O—C(O)R a , OC(O)—OR a , ONH—C(O)O-alkyl, ONHC(O)O-aryl, ONR a R b , SNR a R b , S—ONR a R b , or SO 2 NR a R b ; 
 n is 0, 1, 2, 3, 4, or 5; 
 R 1  is H, NR a R b , Cl, F, OR a , SR a , NHCOR a , NHSO 2 R a , NHCONHR a , CN, alkyl, aryl, ONR a R b , or NR a C(O)OR b ; 
 R 2  is H and R 3  is OH; or R 2  is OH and R 3  is H; 
 R 4  is OH, alkyl-O—, alkylC(═O)O, alkyl-S—, or alkylC(═O)—S—; 
 R 5  is OH, alkyl-O—, alkylC(═O)O, alkyl-S—, or alkylC(═O)—S— 
 R a , R b , R c , and R d  are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, acyl, SO 2 -alkyl and NO; or R a  and R b  together with the nitrogen to which they are attached form a pyrrolidino, piperidino, piperazino, azetidino, morpholino, pyrrolino, or thiomorpholino ring; or R b  and R c  together with the nitrogen to which they are attached form a pyrrolidino, piperidino, piperazino, azetidino, morpholino, pyrrolino, or thiomorpholino ring; 
 R e  is alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, acyl, SO 2 -alkyl or NO; and R f  is H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, acyl, SO 2 -alkyl and NO; or R e  and R f  together with the nitrogen to which they are attached form a pyrrolidino, piperidino, piperazino, azetidino, morpholino, pyrrolino, or thiomorpholino ring; which ring is optionally substituted with one or more halo, hydroxyl, alkyl, alkenyl, or alkynyl; 
 wherein any alkyl, cycloalkyl, alkenyl, alkynyl, or acyl is optionally substituted with 1 to 3 substituents selected from the group consisting of alkoxy, acyl, acylamino, acyloxy, oxyacyl, amino, substituted amino, aminoacyl, aryl, aryloxy, cyano, halogen, hydroxyl, nitro, N 3 , carboxyl, carboxyl esters, thiol, thioalkyl, thioaryl, thioheteroaryl, thiocycloalkyl, thioheterocyclic, cycloalkyl, heteroaryl, and heterocyclic; 
 and wherein any aryl, heteroaryl, or heterocycle is optionally substituted with 1 to 3 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, acyl, acylamino, acyloxy, oxyacyl, amino, substituted amino, aminoacyl, aryl, aryloxy, cyano, halogen, hydroxyl, nitro, N 3 , carboxyl, carboxyl esters, thiol, thioalkyl, thioaryl, thioheteroaryl, thiocycloalkyl, thioheterocyclic, cycloalkyl, heteroaryl, and heterocyclic; 
 or a pharmaceutically acceptable salt or prodrug thereof. 
 
     
     
         28 . The method of  claim 23  wherein the viral infection is hepatitis C. 
     
     
         29 . The method of  claim 27  wherein R is OR a , Cl, SR a , NR e R f , aryl or NR a NR b R C . 
     
     
         30 . The method of  claim 27  wherein R is hydroxy, chloro, methoxy, mercapto, methylthio, methylamino, isopropylamino, propylamino, ethylamino, dimethylamino, cyclopropylamino, 2-aminoethylamino, 1-(2-hydroxyethyl)hydrazino, hydrazino, 1-methylhydrazino, azetidino, pyrrolidino, imidazolylpropylamino, pyrrolino, morpholino, piperazino, hydroxyethylamino, bis-hydroxyethylamino, hydroxypropylamino, hydroxyethylpyrrolidino, or 1-methyl-2-hydroxyethylamino. 
     
     
         31 . The method of  claim 27  wherein R is NR e R f . 
     
     
         32 . The method of  claim 27  wherein the compound is 4-methylamino-7-β-(D-ribofuranosyl)-furo[3,2-d]pyrimidine; 4-Ethylamino-7-β-(D-ribofuranosyl)-furo[3,2-d]pyrimidine; 4-Isopropylamino-7-β-(D-ribofuranosyl)-furo[3,2-d]pyrimidine; 4-Dimethylamino-7-β-(D-ribofuranosyl)-furo[3,2-d]pyrimidine; 4-n-Propylamino-7-β-(D-ribofuranosyl)-furo[3,2-d]pyrimidine; 4-(N-3-pyrrolino)-7-β-(D-ribofuranosyl)-furo[3,2-d]pyrimidine; 4-(2-hydroxymethylpyrrolidino)-7-β-(D-ribofuranosyl)-furo[3,2-d]pyrimidine; 4-(3-N-imidazolyl-n-propylamino)-7-β-(D-ribofuranosyl)-furo[3,2-d]pyrimidine; 4-N-morpholino-7-β-(D-ribofuranosyl)-furo[3,2-d]pyrimidine; 4-N-piperazino-7-β-(D-ribofuranosyl)-furo[3,2-d]pyrimidine; 4-(hydroxyethylamino)-7-β-(D-ribofuranosyl)-furo[3,2-d]pyrimidine; 4-(N-bis-hydroxyethylamino)-7-β-(D-ribofuranosyl)-furo[3,2-d]pyrimidine; 4-(3-hydroxypropylamino)-7-β-(D-ribofuranosyl)-furo[3,2-d]pyrimidine; or 4-(2-hydroxy-1-methyl-ethylamino)-7-β-(D-ribofuranosyl)-furo[3,2-d]pyrimidine; or a pharmaceutically acceptable salt or prodrug thereof. 
     
     
         33 . The method of  claim 23  wherein the compound is a prodrug. 
     
     
         34 . The method of  claim 23  wherein the compound of formula I comprises one or more mono-, di-, or tri-phosphate groups. 
     
     
         35 . The method of  claim 23  wherein the compound of formula I comprises one or more mono-phosphate groups. 
     
     
         36 . The method of  claim 34  wherein the compound is a prodrug. 
     
     
         37 . The method of  claim 34  wherein one or more phosphorous atoms of the one or more pendent mono-, di-, or tri-phosphate groups is bonded to one or more alkoxy or aryloxy groups. 
     
     
         38 . The method of  claim 34  wherein one or more phosphorous atoms of the pendent mono-, di-, or tri-phosphate groups is bonded to one or more groups R y —O—; wherein each R y  is independently a 1-20 carbon branched or unbranched, saturated or unsaturated chain, wherein one or more of the carbon atoms is optionally replaced with —O— or —S— and wherein one or more of the carbon atoms is optionally substituted with oxo (═O) or thioxo (═S). 
     
     
         39 . The method of  claim 34  wherein one or more phosphorous atoms of the one or more pendent mono-, di-, or tri-phosphate groups is bonded to one or more groups R z —N—; wherein each R z  is a residue of an amino acid. 
     
     
         40 . The method of  claim 39  wherein the amino acid is a natural amino acid. 
     
     
         41 . The method of  claim 34  wherein the compound of formula I comprises one or more groups of formula: 
       
         
           
           
               
               
           
         
       
       wherein:
 R 15  is H, alkyl, aryl, cycloalkyl, heteroaryl, heterocyclic, or an amino acid; 
 R 16  is H, aryl, or heteroaryl; and R 17  is H, halogen, CN, —CO—R 20 , —CON(R 21 ) 2 , —CO 2 R 20 , —SO 2 R 20 , —SO 2 N(R 21 ) 2 , —OR 21 , —SR 21 , —R 21 , —N(R 21 ) 2 , —O—COR 20 , —O—CO 2 R 20 , —SCOR 20 , —S—CO 2 R 20 , —NHCOR 21 , —NHCO 2 R 21 , —(CH 2 ) p —OR 22 , or —(CH 2 ) p —SR 22 ; or R 16  and R 17  are connected via an additional 3-5 atoms to form a cyclic group, optionally containing one heteroatom, that is fused to an aryl group at the beta and gamma position to the O attached to the phosphorus; or R 17  and R 18  are connected as described below; 
 R 18  and R 19  are each independently H, alkyl, aryl, aralkyl, aryl, or heteroaryl; or R 18  and R 19  are connected via an additional 2-5 atoms to form a cyclic group, optionally containing 0-2 heteroatoms; or R 17  and R 18  are connected via an additional 3-5 atoms to form a cyclic group, optionally containing one heteroatom and R 19  is H, alkyl, aryl, aralkyl, aryl or heteroaryl; 
 R 20  is alkyl, aryl, or arylalkyl; 
 R 21  is H, alkyl, aryl, or arylalkyl; 
 R 22  is H or lower acyl; 
 p is an integer from 2-3; 
 wherein any alkyl, cycloalkyl, alkenyl, alkynyl, or acyl is optionally substituted with 1 to 3 substituents selected from the group consisting of alkoxy, acyl, acylamino, acyloxy, oxyacyl, amino, substituted amino, aminoacyl, aryl, aryloxy, cyano, halogen, hydroxyl, nitro, N 3 , carboxyl, carboxyl esters, thiol, thioalkyl, thioaryl, thioheteroaryl, thiocycloalkyl, thioheterocyclic, cycloalkyl, heteroaryl, and heterocyclic; 
 and wherein any aryl, heteroaryl, or heterocycle is optionally substituted with 1 to 3 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, acyl, acylamino, acyloxy, oxyacyl, amino, substituted amino, aminoacyl, aryl, aryloxy, cyano, halogen, hydroxyl, nitro, N 3 , carboxyl, carboxyl esters, thiol, thioalkyl, thioaryl, thioheteroaryl, thiocycloalkyl, thioheterocyclic, cycloalkyl, heteroaryl, and heterocyclic. 
 
     
     
         42 . The method of  claim 33  wherein the prodrug is a compound of formula I wherein one or more of R 2 , R 3 , and R 4  is acyloxy, acylamino or R—O; wherein R is a carboxy-linked amino acid. 
     
     
         43 . The method of  claim 23  which further comprises administering to the animal one or more additional viral polymerase inhibitors. 
     
     
         44 . The method  claim 23  which further comprises administering to the animal, one or more protease inhibitors. 
     
     
         45 . The method of  claim 23  which further comprises administering ribavirin to the animal. 
     
     
         46 . The method of  claim 23  which further comprises administering interferon-α or pegylated interferon-α (peginterferon-α) to the animal. 
     
     
         47 . The method of  claim 27  wherein the virus is hepatitis C. 
     
     
         48 . A method for inhibiting an HCV RNA or DNA polymerase comprising contacting the polymerase in vitro or in vivo with an effective inhibitory amount of a compound of formula I or a pharmaceutically acceptable salt or prodrug thereof as described in  claim 23 .